Hospital Pharmacy Europe

SEPTEMBER 4, 2023

The artificial intelligence tool ChatGPT shows great promise in areas such as drug counselling but falls short of clinical pharmacists‘ skills across a range of clinical practice categories, according to a study by Chinese researchers. To date, ChatGPT has been studied in several different areas of healthcare but is not always very effective. For instance, it has been found lacking in its ability to provide answers to cardiovascular questions and suggestions in complex case vignettes.

Adverse Reactions 98

Adverse Reactions Hospitals 98

Outsourcing Pharma

SEPTEMBER 4, 2023

The UK startup Intelligent OMICS (Intellomx) has launched a collaboration with Johnson & Johnsonâs pharmaceutical company Janssen to use artificial intelligence (AI) to discover drug targets for the treatment of blood cancer.

Pharmaceutical Companies 97

Pharmaceutical Companies Pharmaceutical Companies 97

Hospital Pharmacy Europe

SEPTEMBER 4, 2023

The artificial intelligence tool ChatGPT shows great promise in areas such as drug counselling but falls short of clinical pharmacists‘ skills across a range of clinical practice categories, according to a study by Chinese researchers. To date, ChatGPT has been studied in several different areas of healthcare but is not always very effective. For instance, it has been found lacking in its ability to provide answers to cardiovascular questions and suggestions in complex case vignettes.

Adverse Reactions 98

Adverse Reactions Hospitals 98

European Pharmaceutical Review

SEPTEMBER 4, 2023

The National Institute for Health and Care Excellence (NICE) has recommended Chiesi’s Elfabrio ® (pegunigalsidase alfa) for Fabry disease (alpha-galactosidase deficiency) in adults. A new Fabry disease treatment The agreement made in the NICE’s Final Draft Guidance means there is now a “new treatment option for people living with Fabry disease across England,” according to Dr Kamran Iqbal, Head of Medical Affairs for Global Rare Diseases at Chiesi UK&I. “Fabry disease brings a mu

93

93

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Hospital Pharmacy Europe

SEPTEMBER 4, 2023

The use of postnatal selective serotonin reuptake inhibitor (SSRI) treatment is associated with a lower risk of postnatal depression-associated maternal mental health problems and child externalising behaviours, up to five years after childbirth, according to a recent study. Published in the journal JAMA Network Open , the study sought to examine whether postnatal SSRI treatment moderated postnatal depression-associated maternal and child outcomes across early childhood years.

Hospitals 98

Hospitals 98

European Pharmaceutical Review

SEPTEMBER 4, 2023

According to the US Federal Trade Commission (FTC), Amgen is to be barred from leveraging its drug portfolio to disadvantage its industry competitors. The biopharma company will be required to seek prior approval before acquiring related products. The FTC has settled on a proposed consent order with Amgen Inc. to address the potential competitive harm Amgen’s $27.8 billion acquisition of Horizon Therapeutics plc could bring.

88

88

European Pharmaceutical Review

SEPTEMBER 4, 2023

Included in Issue 4 of European Pharmaceutical Review : FOREWORD Dissolution testing – a dual role David Elder, David P Elder Consultancy REGULATORY INSIGHT EU packaging reform: a prescription for change? Maciej Adamczyk and Monika Pyzio-Michalik, DBS Law Firm EVENT PREVIEW Modern methods in microbiology and analytics PharmaLab Congress DRUG DELIVERY Dry powder delivery to the lungs Jnanadeva Bhat, ACG EVENT PREVIEW CPHI Barcelona 2023: what to expect Featuring company profiles from BioSpectra,

Packaging 86

Packaging Vaccines Immunization 86

Hospital Pharmacy Europe

SEPTEMBER 4, 2023

High levels of two enzymes, CD39 and CD73, involved in the adenosine pathway are associated with reduced patient survival in early-stage non-small cell lung cancer (NSCLC) if found in tissue near the tumours , according to the findings of a new study. Understanding the pathways of immune suppression is crucial to the development of new therapeutic targets for immunotherapy.

Immunization 95

Immunization Hospitals 95

Outsourcing Pharma

SEPTEMBER 4, 2023

Less than a month after the U.S. Food and Drug Administration (FDA) gave its antidepressant drug zuranolone (Zurzuvae) a mixed welcome, Sage Therapeutics has launched plans to reorganize its operations by refocusing its drug development efforts and laying off 40% of its workforce.

FDA 84

FDA 84

Pharmaceutical Technology

SEPTEMBER 4, 2023

iNtRON's contract is part of the US Army’s DEVCOM strategy to develop drugs to treat antibiotic-resistant UTIs.

98

98

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Outsourcing Pharma

SEPTEMBER 4, 2023

The small molecule drug alectinib (Alecensa) developed by the big pharma company Roche has improved disease-free survival in patients with a specific form of non-small cell lung cancer (NSCLC) when delivered as an adjuvant therapy in a phase 3 trial.

73

73

pharmaphorum

SEPTEMBER 4, 2023

Ergomed aims to go private via £703m Permira takeover Phil.

115

115

Pharmafile

SEPTEMBER 4, 2023

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited launch. The drug is intended to provide new treatment options to patients living with obesity. The drug will now be available via specialist NHS weight management services for patients meeting the National Institute for Health […] The post Novo Nordisk launches Wegovy in the UK appeared first on Pharmafile.

59

59

pharmaphorum

SEPTEMBER 4, 2023

Patient involvement at NICE: In whose interest is it anyway? Mike.

110

110

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmafile

SEPTEMBER 4, 2023

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) who have already had one prior therapy. The National Medical Products Administration’s (NMPA) approval of this next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor follows positive results from […] The post AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemi

59

59

pharmaphorum

SEPTEMBER 4, 2023

Wegovy finally reaches the UK, in 'limited' quantities Phil.

110

110

Pharmaceutical Technology

SEPTEMBER 4, 2023

The Japanese MHLW has accepted GSK’s supplementary new drug application (sJNDA) for Nucala (mepolizumab) to treat chronic rhinosinusitis

64

64

pharmaphorum

SEPTEMBER 4, 2023

Roche seeks early-stage lung cancer use for Alecensa Phil.

110

110

Outsourcing Pharma

SEPTEMBER 4, 2023

Andrew MacGarvey is chief operating officer (COO) of Phastar. We caught up with him earlier in the summer at DIA Global in Boston to discuss the companyâs origins, opportunities for big analytical data DCTs, artificial intelligence and machine learning among many other topics.

52

52

Roots Analysis

SEPTEMBER 4, 2023

In the recent years, service industry has become a fast-growing segment in the overall healthcare domain – thanks to the steady increase in demand for contract research organizations (CROs) and contract manufacturing organizations. The need to focus on developing more efficient interventions, within stipulated timelines and budget constrains is the key driver for outsourcing operations to third-parties and the diagnostics development space is no exception.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA 52

Pharmaceutical Technology

SEPTEMBER 4, 2023

The company published a study showing lyso-Gb1 (glucosylsphingosine) as a diagnostic and predictive biomarker for the rare metabolic disease.

52

52

pharmaphorum

SEPTEMBER 4, 2023

Nestle sells underperforming peanut allergy drug Phil.

58

58

Pharmaceutical Technology

SEPTEMBER 4, 2023

Bidco has signed an agreement to acquire British biopharmaceutical services company Ergomed in a deal valued at about GBP703.1m ($884.79m).

52

52

Pharma Times

SEPTEMBER 4, 2023

The therapy has been developed for the treatment of Fabry disease among adult patients - News - PharmaTimes

48

48

Pharmaceutical Technology

SEPTEMBER 4, 2023

Biocon Generics has purchased the US-based oral solid dosage manufacturing facility of Eywa Pharma for a total consideration of $7.7m.

Dosage 52

Dosage 52

Pharma Times

SEPTEMBER 4, 2023

The therapy has been developed for the treatment of migraine among adults - News - PharmaTimes

50

50

Pharmaceutical Technology

SEPTEMBER 4, 2023

Amgen and Horizon Therapeutics have reached a consent order agreement with the FTC to resolve the ongoing administrative lawsuit.

52

52

Pharmaceutical Technology

SEPTEMBER 4, 2023

Private Equity firm Permira has announced that it is taking the company private, following many other UK firms.

52

52

Pharmaceutical Technology

SEPTEMBER 4, 2023

The Biden Administration has released the anticipated list of ten drugs selected for Medicare price negotiations under the IRA.

52

52